Comprehensive treatment of lung malignancy for meaningful survival

Abstract

The American Cancer Society estimates, in 2023 there will be an estimated 238,340 new cases of lung cancer in which 117,550 cases in men and 120,790 cases in women. Non-Small-Cell Lung Cancer (NSCLC) is a prevalent type of lung cancer, accounting for approximately 80% of all reported lung malignancy cases and characterized by a poor 5-year survival rate. Lung cancer detected in early stages with prompt diagnosis and appropriate treatment will improve the patient's life expectancy. According to current data, patients admitted to the hospital with lung cancer in an advanced stage. Platinum-based chemotherapy is widely regarded as the gold standard of therapy for patients with advanced lung cancer across the world. Chemotherapy not only eliminates cancer cells, but also affects actively proliferating normal cells, such as hematopoietic cells in the bone marrow. Stem cells that secrete granulocytes, erythrocytes and platelets in the peripheral circulation will be harmed as well. Further research and new discoveries are required for treatment approaches that are projected to reduce the problem of adverse survivorship bias and improve the quality of life for lung cancer patients. Several targeted therapies, such as EGFR tyrosine kinase inhibitors and ALK inhibitors, have demonstrated significant clinical success in treating NSCLC patients with the corresponding gene mutations.